Pharmacotherapy of Zollinger-Ellison syndrome

Tetsuhide Ito, Hisato Igarashi, Hirotsugu Uehara, Robert T. Jensen

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Introduction: The role of pharmacotherapy in the management of patients with Zollinger-Ellison syndrome (ZES) is often equated with the medical management of acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients. Areas covered: This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is the role of pharmacotherapy in controlling acid hypersecretion and other hormonal hypersecretory states these patients may develop, including hyperparathyroidism in patients with multiple endocrine neoplasia type 1 and ZES; tumor localization; and the treatment of advanced metastatic disease. The last includes chemotherapy, liver-directed therapies, biotherapy (somatostatin/ interferon), peptide radio-receptor therapy and molecular-targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib). Expert opinion: Pharmacotherapy is now involved in all aspects of the management of patients with ZES, with the result that ZES has progressed from being considered an entirely surgical disease initially to the present where medical treatment plays a major role in almost all aspects of the management of these patients.

Original languageEnglish
Pages (from-to)307-321
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number3
DOIs
Publication statusPublished - Feb 1 2013

Fingerprint

Zollinger-Ellison Syndrome
Drug Therapy
Molecular Targeted Therapy
Multiple Endocrine Neoplasia Type 1
Biological Therapy
Acids
Peptide Receptors
Hyperparathyroidism
Proton Pump Inhibitors
Expert Testimony
Therapeutics
Somatostatin
Radio
Protein-Tyrosine Kinases
Interferons
Liver

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacotherapy of Zollinger-Ellison syndrome. / Ito, Tetsuhide; Igarashi, Hisato; Uehara, Hirotsugu; Jensen, Robert T.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 3, 01.02.2013, p. 307-321.

Research output: Contribution to journalReview article

Ito, T, Igarashi, H, Uehara, H & Jensen, RT 2013, 'Pharmacotherapy of Zollinger-Ellison syndrome', Expert Opinion on Pharmacotherapy, vol. 14, no. 3, pp. 307-321. https://doi.org/10.1517/14656566.2013.767332
Ito, Tetsuhide ; Igarashi, Hisato ; Uehara, Hirotsugu ; Jensen, Robert T. / Pharmacotherapy of Zollinger-Ellison syndrome. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 3. pp. 307-321.
@article{715b5c2f11864319a9e9b9a9fa3e3952,
title = "Pharmacotherapy of Zollinger-Ellison syndrome",
abstract = "Introduction: The role of pharmacotherapy in the management of patients with Zollinger-Ellison syndrome (ZES) is often equated with the medical management of acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients. Areas covered: This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is the role of pharmacotherapy in controlling acid hypersecretion and other hormonal hypersecretory states these patients may develop, including hyperparathyroidism in patients with multiple endocrine neoplasia type 1 and ZES; tumor localization; and the treatment of advanced metastatic disease. The last includes chemotherapy, liver-directed therapies, biotherapy (somatostatin/ interferon), peptide radio-receptor therapy and molecular-targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib). Expert opinion: Pharmacotherapy is now involved in all aspects of the management of patients with ZES, with the result that ZES has progressed from being considered an entirely surgical disease initially to the present where medical treatment plays a major role in almost all aspects of the management of these patients.",
author = "Tetsuhide Ito and Hisato Igarashi and Hirotsugu Uehara and Jensen, {Robert T.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1517/14656566.2013.767332",
language = "English",
volume = "14",
pages = "307--321",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Pharmacotherapy of Zollinger-Ellison syndrome

AU - Ito, Tetsuhide

AU - Igarashi, Hisato

AU - Uehara, Hirotsugu

AU - Jensen, Robert T.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Introduction: The role of pharmacotherapy in the management of patients with Zollinger-Ellison syndrome (ZES) is often equated with the medical management of acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients. Areas covered: This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is the role of pharmacotherapy in controlling acid hypersecretion and other hormonal hypersecretory states these patients may develop, including hyperparathyroidism in patients with multiple endocrine neoplasia type 1 and ZES; tumor localization; and the treatment of advanced metastatic disease. The last includes chemotherapy, liver-directed therapies, biotherapy (somatostatin/ interferon), peptide radio-receptor therapy and molecular-targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib). Expert opinion: Pharmacotherapy is now involved in all aspects of the management of patients with ZES, with the result that ZES has progressed from being considered an entirely surgical disease initially to the present where medical treatment plays a major role in almost all aspects of the management of these patients.

AB - Introduction: The role of pharmacotherapy in the management of patients with Zollinger-Ellison syndrome (ZES) is often equated with the medical management of acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients. Areas covered: This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is the role of pharmacotherapy in controlling acid hypersecretion and other hormonal hypersecretory states these patients may develop, including hyperparathyroidism in patients with multiple endocrine neoplasia type 1 and ZES; tumor localization; and the treatment of advanced metastatic disease. The last includes chemotherapy, liver-directed therapies, biotherapy (somatostatin/ interferon), peptide radio-receptor therapy and molecular-targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib). Expert opinion: Pharmacotherapy is now involved in all aspects of the management of patients with ZES, with the result that ZES has progressed from being considered an entirely surgical disease initially to the present where medical treatment plays a major role in almost all aspects of the management of these patients.

UR - http://www.scopus.com/inward/record.url?scp=84873389357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873389357&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.767332

DO - 10.1517/14656566.2013.767332

M3 - Review article

VL - 14

SP - 307

EP - 321

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -